Intravitreal anti-VEGF ranibizumab rapidly resolves spontaneous hyphema and reduces IOP in Fuch's heterochromic iridocyclitis.
Background
Fuch's heterochromic iridocyclitis (FHI) is a chronic, low-grade anterior uveitis, often unilateral, with unclear etiology. A significant complication is Amsler's sign, characterized by spontaneous hyphema, which can lead to ocular hypertension and secondary glaucoma. Current management primarily addresses these complications rather than the underlying inflammation. There's a clinical gap for targeted therapies that can directly resolve acute complications like hyphema and refractory ocular hypertension, especially when standard medical therapies fail.
Study Design
This case report describes a single patient diagnosed with Fuch's heterochromic iridocyclitis (FHI) who presented with spontaneous hyphema and acute-on-chronic ocular hypertension. The ocular hypertension was refractory to conventional medical therapy. The patient received an intravitreal injection of ranibizumab, an anti-vascular endothelial growth factor (anti-VEGF) agent. The primary endpoints observed were the resolution of hyphema and changes in intraocular pressure (IOP). Subsequent management included trabeculectomy for definitive control of persistent chronic ocular hypertension.
Results
Intravitreal ranibizumab therapy achieved a rapid resolution of the spontaneous hyphema. This resolution was accompanied by a significant reduction in intraocular pressure (IOP). The abstract highlights the effectiveness of anti-VEGF therapy in addressing the acute complications of FHI. While specific quantitative data on the magnitude of IOP reduction or the timeline for hyphema resolution are not provided in the abstract, the qualitative description emphasizes a prompt and positive response to the treatment. This suggests a direct impact on the vascular pathology contributing to the hyphema and elevated IOP. The patient ultimately required a trabeculectomy for long-term management of chronic ocular hypertension, indicating the ranibizumab addressed the acute phase.
Intravitreal anti-VEGF ranibizumab achieved rapid resolution of hyphaema with resultant reduction in IOP.
Key Findings
- Intravitreal ranibizumab rapidly resolved spontaneous hyphema in a patient with FHI.
- Ranibizumab treatment led to a reduction in intraocular pressure (IOP).
- Anti-VEGF therapy served as a successful adjunctive strategy for refractory ocular hypertension.
- The patient subsequently required trabeculectomy for definitive chronic IOP control.
Why It Matters
This case report suggests that anti-VEGF therapy with ranibizumab could be a valuable adjunctive strategy for patients with Fuch's heterochromic iridocyclitis (FHI) complicated by spontaneous hyphema and refractory ocular hypertension. For clinicians, this offers a potential acute intervention to rapidly stabilize ocular conditions that are unresponsive to standard medical treatments. While not a definitive cure for FHI or chronic glaucoma, it provides a tool to manage severe acute complications, potentially preventing further damage. This approach could be integrated into existing protocols for FHI management, particularly in cases presenting with Amsler's sign and acute IOP spikes, offering a rapid-acting option to mitigate immediate risks before considering surgical interventions.
ranibizumab
fuchs-heterochromic-iridocyclitis
hyphema
ocular-hypertension
anti-vegf
uveitis